146 related articles for article (PubMed ID: 9462312)
1. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.
Sarasin FP; Bounameaux H
BMJ; 1998 Jan; 316(7125):95-9. PubMed ID: 9462312
[TBL] [Abstract][Full Text] [Related]
2. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
[TBL] [Abstract][Full Text] [Related]
4. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.
Eckman MH; Singh SK; Erban JK; Kao G
Med Decis Making; 2002; 22(2):108-24. PubMed ID: 11958494
[TBL] [Abstract][Full Text] [Related]
5. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 1994 Mar; 71(3):286-91. PubMed ID: 8029791
[TBL] [Abstract][Full Text] [Related]
6. Duration of anticoagulant treatment for venous thrombosis.
Raskob GE
Curr Opin Pulm Med; 1997 Jul; 3(4):286-90. PubMed ID: 9262115
[TBL] [Abstract][Full Text] [Related]
7. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.
Marchetti M; Pistorio A; Barosi G
Thromb Haemost; 2000 Nov; 84(5):752-7. PubMed ID: 11127850
[TBL] [Abstract][Full Text] [Related]
8. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
[TBL] [Abstract][Full Text] [Related]
9. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.
Ridker PM
Vasc Med; 1998; 3(1):67-73. PubMed ID: 9666536
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.
Donovan AK; Smith KJ; Ragni MV
Thromb Res; 2013; 132(6):724-8. PubMed ID: 24112753
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.
Pinede L; Ninet J; Duhaut P; Chabaud S; Demolombe-Rague S; Durieu I; Nony P; Sanson C; Boissel JP;
Circulation; 2001 May; 103(20):2453-60. PubMed ID: 11369685
[TBL] [Abstract][Full Text] [Related]
12. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
[TBL] [Abstract][Full Text] [Related]
13. [Duration of oral anticoagulant therapy in deep venous thrombosis of the lower limbs].
Pinède L
Ann Cardiol Angeiol (Paris); 2002 Jun; 51(3):158-63. PubMed ID: 12471647
[TBL] [Abstract][Full Text] [Related]
14. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
15. Recurrent venous thrombosis with factor V Leiden mutation.
Meenakshi-Sundaram S; Sridhar R; Jithendrian JJ; Durai RN; Arunkumar MJ; Sundar B
J Assoc Physicians India; 2005 Jul; 53():642-4. PubMed ID: 16190136
[TBL] [Abstract][Full Text] [Related]
16. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
Simioni P; Prandoni P; Lensing AW; Scudeller A; Sardella C; Prins MH; Villalta S; Dazzi F; Girolami A
N Engl J Med; 1997 Feb; 336(6):399-403. PubMed ID: 9010145
[TBL] [Abstract][Full Text] [Related]
17. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
Turkstra F; Karemaker R; Kuijer PM; Prins MH; Büller HR
Thromb Haemost; 1999 Mar; 81(3):345-8. PubMed ID: 10102457
[TBL] [Abstract][Full Text] [Related]
18. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
Manten B; Westendorp RG; Koster T; Reitsma PH; Rosendaal FR
Thromb Haemost; 1996 Oct; 76(4):510-3. PubMed ID: 8902987
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis.
Sarasin FP; Bounameaux H
Arch Intern Med; 1996 Aug 12-26; 156(15):1661-8. PubMed ID: 8694664
[TBL] [Abstract][Full Text] [Related]
20. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis.
Andersen BS; Olsen J
Thromb Res; 1998 May; 90(4):191-4. PubMed ID: 9692618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
